In the second half of 2023, the Company expects to: Announce interim efficacy data from HBV003, a Phase 2b clinical trial of VTP-300, that further evaluates its potential as a component of a functional cure for chronic Hepatitis B. Announce interim efficacy data from the Phase 2a clinical trial collaboration with Arbutus of VTP-300 in combination with Arbutus’ siRNA therapeutic candidate, AB-729 for chronic hepatitis B. Submit an Investigational New Drug application for VTP-1000, the Company’s lead SNAPvax technology candidate, for the treatment of celiac disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VACC:
- Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
- Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
- Vaccitech doses first patient in PCA001 Phase 1/2 trial of VTP-850
- Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy
